NextCure (NASDAQ:NXTC – Get Free Report) announced its earnings results on Thursday. The company reported ($2.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85), FiscalAI reports.
NextCure Price Performance
Shares of NASDAQ:NXTC traded up $0.25 during mid-day trading on Friday, hitting $5.84. The company had a trading volume of 290,316 shares, compared to its average volume of 6,419,686. NextCure has a one year low of $1.55 and a one year high of $15.74. The firm has a fifty day moving average price of $3.35 and a 200 day moving average price of $8.41. The company has a market capitalization of $21.08 million, a PE ratio of -0.67 and a beta of 1.27.
Insider Transactions at NextCure
In related news, major shareholder Adar1 Capital Management, Llc purchased 292,850 shares of NextCure stock in a transaction on Thursday, July 30th. The stock was acquired at an average cost of $4.93 per share, for a total transaction of $1,443,750.50. Following the completion of the acquisition, the insider owned 686,116 shares of the company’s stock, valued at $3,382,551.88. This trade represents a 74.47% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have acquired 346,761 shares of company stock worth $1,710,807 over the last 90 days. 11.90% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On NextCure
Analyst Ratings Changes
A number of analysts have commented on the stock. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of NextCure in a research report on Wednesday, July 15th. Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen lowered NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $19.00.
Read Our Latest Stock Analysis on NXTC
About NextCure
NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.
The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.
Featured Stories
- Five stocks we like better than NextCure
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
